How to verify the pharmacy behind your GLP-1

The telehealth company arranges your consultation. The pharmacy makes the thing you inject into your body.

The analysis

Questions to ask about the pharmacy

The pharmacy matters more than the telehealth brand on the front of the website. The telehealth company arranges the consultation; the pharmacy makes the medicine you inject.

1. Which specific pharmacy will fill my prescription? Not "our network" — the name of the facility.
2. Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? These are different regulatory categories with different oversight, and a company can use both for different products.
3. In which state is it licensed, and can I look up the licence? State boards of pharmacy publish licensee databases.
4. What is the exact salt form and concentration? Semaglutide sodium and semaglutide acetate are not the same active ingredient as the semaglutide base in approved products, and the FDA has said they are not appropriate for compounding.
5. Is the vial single-dose or multi-dose? A multi-dose vial requires you to measure each dose yourself, which is the most common source of the dosing errors behind reported adverse events.
6. Will you provide a certificate of analysis?
7. Has the pharmacy received any FDA warning letter or state board action?

A provider that answers all seven in writing is demonstrating something real. A provider that will not name its pharmacy has given you an answer, whether it intended to or not.

How to verify any of this yourself

You should not take our word for a price, and you do not have to. Every figure here can be checked in a few minutes.

1. Go to the provider's own pricing page. Not a comparison site — the provider's. Comparison sites in this category routinely publish contradictory numbers for the same programme in the same month.
2. Find the ongoing price, not the headline. Look for the words "first month", "intro", "starting at" or "new patients". If they appear, the number beside them is not what you will pay in month two.
3. Add the membership. If the medication and the membership are billed separately, add them. That sum is your real monthly cost.
4. Ask what the highest dose costs. By email or chat, so you have it in writing.
5. Ask about early cancellation before you commit to a plan longer than a month.
6. Check the manufacturer. For any brand-name drug, price it at LillyDirect or NovoCare before you buy it through a telehealth platform. Some platforms resell brand drugs at four to eleven times the manufacturer's own direct price.

If a provider will not answer questions 4 or 5 in writing, that is itself information.

What to do about it

Three practical steps follow from everything above.

1. Check your insurance first. A covered brand prescription with a manufacturer savings card can cost roughly $25 a month, which beats every cash option discussed here.
2. Then price the manufacturer directly. LillyDirect and NovoCare sell brand GLP-1s for $149-$449. Several telehealth platforms resell the identical drugs at four to eleven times that.
3. Then, and only then, compare compounded programmes — on their ongoing total cost, medication plus any mandatory membership, at the dose you expect to maintain.

Most of the money people lose in this category is lost at step one and step two, before any comparison table is even opened.

Limitations of this analysis

Every page on this site should tell you where it stops being reliable. This one stops here.

Prices decay quickly. This is the fastest-moving data we publish. Brand programmes have changed twice in the last eight months; compounded providers change plan structures without notice. Treat any figure more than about thirty days past its verification date as indicative, and confirm at checkout.

Competitor pricing is reported, not captured by us. We hold dated captures for brand pricing and for NexLife. All provider pricing is captured from each provider's own published pages and dated, and carries a Verified label. Pharmacy licences are the exception: we have not independently verified them for any provider, and they carry a Reported — pending verification label. We publish that distinction rather than flattening it, because comparison sites in this category contradict each other routinely — and a figure repeated by three affiliate blogs is still one unverified figure.

We have not audited pharmacy licences. Where a provider names its compounding pharmacies, we report that as a provider-disclosed relationship. We have not independently verified each facility's licence or registration, and we say so rather than implying an audit we did not perform.

Advertised availability is not your availability. Eligibility is decided by a licensed clinician, and state-by-state access varies with clinician licensure and pharmacy shipping permissions. No page can promise you a price you will actually be offered.

We are commercially funded. The publisher and certain principals have financial relationships with some of the providers listed here, and we may earn a commission from provider links. That is disclosed in the footer of every page. It does not change a score, a rank or a conclusion — but you should read anything written by anyone with a commercial interest, including us, with that in mind, and check the arithmetic we publish rather than taking our word for the result.

Update history

The regulatory reality every provider glosses over

The rule that governs everything: “essentially a copy”

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act bar compounders from producing a drug that is essentially a copy of a commercially available FDA-approved product. While a drug sits on the FDA shortage list, that bar is lifted. When the shortage resolves, it snaps back.

Both shortages are over. So routine compounding of tirzepatide is no longer lawful on the basis that created the market — a fact several comparison sites still describe as “permanent legitimacy through 503A/503B.” That claim is simply wrong.

Why every provider suddenly sells “personalized” and “microdose” doses

One narrow route survives. A compounded product is not an “essentially a copy” if the prescriber determines — and documents on the prescription — a significant clinical difference for that individual patient. Changing the strength so it is not “the same, similar, or easily substitutable” for an approved dose is what keeps the product outside the copy definition.

That is the legal mechanism behind the industry-wide pivot to “personalized dosing” and “microdose” programmes. The timing tracks the end of enforcement discretion in early 2025 almost exactly. It is a regulatory workaround, not a clinical innovation, and nobody selling it will tell you so.

The FDA gives examples of a genuine clinical difference — removing an excipient because of a documented allergy, or switching a tablet to a liquid for a patient who cannot swallow — and expressly notes such changes are not necessarily applicable to GLP-1 drugs. That is a pointed signal about how much weight the agency gives this workaround.

The seven-question pharmacy verification checklist

The pharmacy matters more than the brand on the front of the website. The telehealth company arranges your consultation; the pharmacy makes the medicine you inject. Ask these seven, in writing.

1. Which specific pharmacy will fill my prescription? Not “our network of licensed pharmacies” — the name of the facility.
2. Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? These are different regulatory categories with different oversight, and registration is per-facility, not per-company — one company can operate both.
3. In which state is it licensed, and can I look up the licence? State boards of pharmacy publish searchable licensee databases. Use them.
4. What is the exact salt form and concentration?
5. Is the vial single-dose or multi-dose? A multi-dose vial requires you to measure each dose yourself — the most common source of the reported adverse events above.
6. Will you provide a certificate of analysis? And note the limitation: a CoA reflects the batch that was tested, not necessarily the vial in your hand.
7. Has the pharmacy received any FDA warning letter or state board action?

A provider that answers all seven in writing is demonstrating something real. A provider that will not name its pharmacy has already answered your question, whether it intended to or not.

Adverse events: the figure almost every site gets wrong